Joshua M. Eizen - 26 Feb 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Operating Officer and Chief Legal Officer
Signature
/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen
Issuer symbol
ANTX
Transactions as of
26 Feb 2025
Transactions value $
$0
Form type
4
Filing time
28 Feb 2025, 16:22:55
Previous filing
07 Jan 2025
Next filing
06 Nov 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +58.5K +50.14% $0.00 175K 26 Feb 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +117K $0.00 117K 26 Feb 2025 Common Stock 117K $1.13 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.
F2 Includes (a) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 (b) 22,500 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025 and (c) 45,000 RSUs which vest as follows: 2/3rd of the RSU vest on January 1, 2026 and 1/3rd of the RSUs vest on July 1, 2026, subject to the Reporting Person's continuous service as of such date.
F3 The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.

Remarks:

Chief Operating Officer and Chief Legal Officer